logo

For the Inventor, By the Inventor

Northbrook, IL, United States of America

Robert B Garland

This inventor holds 23 USPTO granted patents, plus 2 CIPO patents, primarily in Platelet Aggregation Inhibitors. Top assignees: G.d. Searle & Company, National Research Development Corporation, Monsanto Company. Active years: 1976-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert B Garland. Retrieved from https://idiyas.com/inventor/robert-b-garland

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.4

ph-index = 7

Forward Citations = 171(Granted Patents)


Company Filing History:

goldMedal16 out of 1,323 
 
G.d. Searle & Company
 patents
silverMedal6 out of 1,200 
 
National Research Development Corporation
 patents
bronzeMedal2 out of 3,289 
 
Monsanto Company
 patents
4. 1 out of 4,188 
 
Abbott Laboratories Corporation
 patents
where one patent can have more than one assignee

Years Active: 1976-1998

Loading Chart...
Loading Chart...
Areas of Expertise:
Platelet Aggregation Inhibitors
Thromboxane A2 Antagonists
Peptide Mimetic Compounds
Phenyl Amidines Derivatives
Indolyl Inhibitors
Pyridyl Peptide Mimics
Benzopyran Intermediates
Fluoroprostacyclins
Daunorubicin Analogs
Pharmaceutical Compositions
Synthesis Methods
23 patents (USPTO):Explore Patents
1. 5721366 - Platelet aggregation inhibitors (1998-02-24),
2. 5552431 - Peptide mimetic compounds useful as platelet aggregation inhibitors (1996-09-03),
3. 5550159 - Peptide mimics useful as platelet aggregation inhibitors (1996-08-27),
4. 5486525 - Platelet activating factor antagonists: imidazopyridine indoles (1996-01-23),
5. 5481021 - Phenyl amidines derivatives useful as platelet aggregation inhibitors (1996-01-02),
6. 5453440 - Peptide mimics useful as platelet aggregation inhibitors (1995-09-26),
7. 5424334 - Peptide mimetic compounds useful as platelet aggregation inhibitors (1995-06-13),
8. 5220050 - Peptide mimetic compounds useful as platelet aggregation inhibitors (1993-06-15),
9. 5106870 - Methods for the use of thromboxane A.sub.2 antagonists (1992-04-21),
10. 5091396 - Pyridyl peptide mimetic compounds which are useful platelet-aggregation (1992-02-25),
11. 5055582 - Process for preparing thromboxane A.sub.2 antagonists (1991-10-08),
12. 5037808 - Indolyl platelet-aggregation inhibitors (1991-08-06),
13. 4992581 - Novel methods of manufacturing thromboxane A.sub.2 antagonists (1991-02-12),
14. 4992563 - Benzopyran intermediates for use in manufacturing thromboxane A.sub.2 (1991-02-12),
15. 4973604 - Thromboxane A.sub.2 antagonists and pharmaceutical compositions thereof (1990-11-27),

Title: The Inventor Spotlight - Robert B Garland from Northbrook, IL

Introduction:

Robert B Garland, a prolific inventor hailing from Northbrook, IL, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 23 patents to his name. His inventive spirit and dedication to advancing medical science have led to groundbreaking discoveries in platelet aggregation inhibition.

Latest Patents:

One of Garland's latest patents includes the development of peptide mimetic compounds that serve as effective platelet aggregation inhibitors. These compounds, with their unique chemical structures, hold promise in the realm of cardiovascular health and pharmaceutical interventions.

Career Highlights:

Garland's illustrious career has seen him working with esteemed organizations such as G.D. Searle & Company and the National Research Development Corporation. His tenure at these institutions provided him with the platform to pursue his passion for innovation and drug discovery.

Collaborations:

During his professional journey, Garland collaborated closely with notable peers in the field, including Masateru Miyano and Foe S Tjoeng. These collaborations played a pivotal role in the successful development and commercialization of his inventive concepts.

Conclusion:

In conclusion, Robert B Garland's pioneering work in the pharmaceutical sector stands as a testament to his unwavering commitment to scientific exploration and inventiveness. His patents and collaborations have left an indelible mark on the landscape of medical innovation, solidifying his legacy as a trailblazing inventor in the realm of platelet aggregation inhibitors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…